Jessica Febles
Family Medicine · Atlanta, GANPI 1679167258
Payments from drug & device makers
Across 102 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$324
- Novo Nordisk$230
- AbbVie$208
- Galderma Laboratories, L.p.$174
- Shield Therapeutics Inc$172
- GSK$169
- plus $809 from 16 others
What the payments were for
- Food & beverage$2,06699%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 15 | $324 |
| Novo Nordisk | 15 | $230 |
| AbbVie | 12 | $208 |
| Galderma Laboratories, L.p. | 1 | $174 |
| Shield Therapeutics Inc | 8 | $172 |
| GSK | 7 | $169 |
| Paratek Pharmaceuticals, Inc. | 7 | $125 |
| Lilly USA, LLC | 7 | $120 |
| Amgen | 6 | $107 |
| AstraZeneca | 5 | $78 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $66 |
| Pfizer | 2 | $43 |
| Johnson & Johnson | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Exact Sciences | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Corcept Therapeutics | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
How this compares
$2,086 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 16 | $65,554 |
| JardianceEmpagliflozin | 19 | $28,429 |
| OzempicSemaglutide | 13 | $16,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,458 |
| EliquisApixaban | 14 | $13,750 |
| Carbamazepine ErCarbamazepine | 11 | $1,720 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,611 |
| Rosuvastatin Calcium | 116 | $1,233 |
| Gabapentin | 38 | $1,006 |
| Atorvastatin Calcium | 121 | $838 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $741 |
| Diclofenac Sodium | 42 | $661 |
| Omeprazole | 58 | $606 |
| Olanzapine | 17 | $568 |
| Triamcinolone Acetonide | 36 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $230 | $16,62213 claims |
| GSKTrelegy Ellipta | $169 | $14,45819 claims |
| PfizerEliquis | $43 | $13,75014 claims |
| Lilly USA, LLCOlanzapine | $120 | $56817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Atlanta
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Nadia CameronAtlanta$2.1M
- Otis PowellAtlanta$608K
- Thinh NguyenAtlanta$427K
- Patricia MarshAtlanta$175K
- Contessa MetcalfeAtlanta$157K
- Michelle EvansAtlanta$127K
- Mark TannerAtlanta$94K
- Ambar KulshreshthaAtlanta$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.